Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-041059
Filing Date
2019-11-06
Accepted
2019-11-06 16:25:21
Documents
62
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q aimt-10q_20190930.htm   iXBRL 10-Q 3121667
2 EX-31.1 aimt-ex311_9.htm EX-31.1 19449
3 EX-31.2 aimt-ex312_10.htm EX-31.2 19454
4 EX-32.1 aimt-ex321_6.htm EX-32.1 16893
  Complete submission text file 0001564590-19-041059.txt   9944308

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA aimt-20190930.xsd EX-101.SCH 56762
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE aimt-20190930_cal.xml EX-101.CAL 79997
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE aimt-20190930_def.xml EX-101.DEF 164932
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE aimt-20190930_lab.xml EX-101.LAB 491589
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aimt-20190930_pre.xml EX-101.PRE 352263
10 EXTRACTED XBRL INSTANCE DOCUMENT aimt-10q_20190930_htm.xml XML 1943823
Mailing Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884
Business Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884 (650) 614-5220
Aimmune Therapeutics, Inc. (Filer) CIK: 0001631650 (see all company filings)

EIN.: 452748244 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37519 | Film No.: 191196679
SIC: 2834 Pharmaceutical Preparations